Dynavax Technologies Corp (DVAX)
9.985
+0.12
(+1.17%)
USD |
NASDAQ |
Mar 21, 10:16
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 1.275B |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| All-Time High (Daily) | Upgrade |
| Year to Date Total Returns (Daily) | Upgrade |
| 1 Month Total Returns (Daily) | Upgrade |
| 1 Year Total Returns (Daily) | -16.43% |
| Valuation | |
| PE Ratio | 5.069 |
| PE Ratio (Forward) | Upgrade |
| PS Ratio | 2.082 |
| Price to Book Value | 2.194 |
| EV to EBITDA | Upgrade |
| Dividend | |
|---|---|
| Dividend | -- |
| Dividend Yield (Forward) | Upgrade |
| Financials | |
| Revenue (5 Year Growth) | Upgrade |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (5 Year Growth) | Upgrade |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Debt to Equity Ratio | 0.3814 |
| Return on Equity | Upgrade |
| Return on Assets | Upgrade |
| Risk | |
| Beta (5Y) | Upgrade |
| Max Drawdown (5Y) | 92.83% |
News
Headline
Wire
Time (ET)
MT Newswires
02/28 15:31
Yahoo
02/28 08:00
Yahoo
02/26 07:30
MT Newswires
02/24 11:24
MT Newswires
02/24 10:26
Events
| DATE | TIME | TYPE | PERIOD | REPORTED EPS |
ESTIMATED EPS |
SURPRISE | |
| 05/05/2023* | 16:30 EST | Earnings Call | Q1 2023 | -- | -- | -- | |
| 05/05/2023* | -- | Results | Q1 2023 | -- | -0.13 | -- | |
| 02/23/2023 | 16:30 EST | Earnings Call | Q4 2022 | -- | -- | -- | |
| 02/23/2023 | -- | Results | Q4 2022 | 0.45 | 0.44 | 1.50% | |
| 11/03/2022 | 16:30 EST | Earnings Call | Q3 2022 | -- | -- | -- | |
| 11/03/2022 | -- | Results | Q3 2022 | 0.43 | 0.28 | 56.36% | |
| 08/04/2022 | -- | Results | Q2 2022 | 0.85 | 0.32 | 163.6% | |
| 08/04/2022 | 16:30 EST | Earnings Call | Q2 2022 | -- | -- | -- |
*Estimated Date/Time
Earnings
Profile
Edit
| Dynavax Technologies Corp is a biopharmaceutical company. The company focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor stimulation. Its current product candidates are being investigated for use in multiple cancer indications as a vaccine for the prevention of HEPLISAV-B (Hepatitis B Vaccine (Recombinant), Adjuvanted), operates in the business segment of discovery, development, and commercialization of novel vaccines. Its Toll-like Receptor Immune Modulation Platform technology plays a vital role in innate immunity and subsequent adaptive immunity. The company generates the vast majority of its revenue from the sale of its CpG 1018 product and HEPLISAV-B. |
| URL | https://www.dynavax.com |
| Investor Relations URL | https://investors.dynavax.com |
| HQ State/Province | California |
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| Equity Style | Small Cap/Growth |
| Next Earnings Release | May. 05, 2023 (est.) |
| Last Earnings Release | Feb. 23, 2023 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Analyst Coverage
|
Consensus Rating
|
|
|
Analyst Recommendation
|
|
Source: S&P Global
Dividends
| Dividend Per Share (TTM) | -- |
|
2017
2018
2019
2020
2021
6.00%
4.00%
2.00%
|
|
| Yield to Market | 0.00 |
| Yield to Sector | 0.00 |
| Yield to Industry | 0.00 |
| Last Dividend Amt. | -- |
| Dividend Frequency | -- |
| Last Ex-Dividend Date | -- |
| Yield (TTM) | 0% |
| Forward Yield | -- |
| Payout Ratio | 0.00% |
| Cash Payout Ratio | 0.00% |
| Consistent Payer (5Y) | No |
| Consistent Growth (5Y) | No |
Risk
Total Returns Comparison
Annual Total Returns Versus Peers
As of March 20, 2023.
Fundamentals
| Revenue (TTM) | 722.68M |
| Total Expenses (TTM) | 440.16M |
| Net Income (TTM) | 293.16M |
| Total Assets (Quarterly) | 985.85M |
| Total Liabilities (Quarterly) | 404.84M |
| Shareholders Equity (Quarterly) | 581.01M |
| Cash from Operations (TTM) | 62.72M |
| Cash from Investing (TTM) | -316.00M |
| Cash from Financing (TTM) | 19.52M |
Ratings
Profile
Edit
| Dynavax Technologies Corp is a biopharmaceutical company. The company focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor stimulation. Its current product candidates are being investigated for use in multiple cancer indications as a vaccine for the prevention of HEPLISAV-B (Hepatitis B Vaccine (Recombinant), Adjuvanted), operates in the business segment of discovery, development, and commercialization of novel vaccines. Its Toll-like Receptor Immune Modulation Platform technology plays a vital role in innate immunity and subsequent adaptive immunity. The company generates the vast majority of its revenue from the sale of its CpG 1018 product and HEPLISAV-B. |
| URL | https://www.dynavax.com |
| Investor Relations URL | https://investors.dynavax.com |
| HQ State/Province | California |
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| Equity Style | Small Cap/Growth |
| Next Earnings Release | May. 05, 2023 (est.) |
| Last Earnings Release | Feb. 23, 2023 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Ownership
| Insider Ownership Percentage | Upgrade |
Jul '20
Nov '20
Mar '21
80.00%
40.00%
10.00%
Analyst Coverage
|
Consensus Rating
|
|
|
Analyst Recommendation
|
|
Source: S&P Global
Other Resources
| Whale Wisdom | 13F Filings |
| Seeking Alpha | Call Transcripts |
| Nasdaq | Insider Trading |
| Nasdaq | Institutional Ownership |
| Nasdaq | Option Chain |
| SEC | SEC Filings |
| DVAX Tweets |